A federal judge in New Jersey ruled Wednesday that PTC Therapeutics should allow a 16-year-old patient with Duchenne muscular dystrophy to use its experimental medicine even though he does not meet the company's criteria to be a part of the drug's clinical trial. The decision could encourage patients seeking access to clinical studies to file lawsuits against drugmakers, PTC CEO Stuart W. Peltz said.

Full Story:

Related Summaries